Read full article: A phase 2 trial tested TIL therapy in metastatic uveal melanoma Response rates were 37% with reactive TIL vs. 0% without Responses lasted a median of 17.3 months A pre-surgery biopsy score, UMIS, helped predict who responded Researchers are now [...]
Read full article: Uveal melanoma's distinct biology has made it resist systemic treatment HLA-A*02:01–negative patients have historically had limited options Past choices: liver-directed therapy, off-label combos, or clinical trials OptimUM-02 tested darovasertib plus crizotinib vs. investigator's choice More emerging options are making treatment [...]
Harbour Lab Tour: Attendees stepped inside UT Southwestern's lab to meet the scientists studying ocular melanoma. HEPZATO Demonstration: Drs. Chandrasekaran and Shannon led a closer look at liver-directed treatment for metastatic disease. Expert Medical Program: Sessions covered surveillance, biomarkers, adjuvant therapy, treatment sequencing, [...]
Read full article: Jefferson researchers tested defactinib plus avutometinib in 12 MUM patients The drug pairing was selected using "synthetic lethality analysis" Tumors didn't shrink: six stayed stable and six progressed The enzyme ALDH1A3 rose in several patients whose disease progressed The findings [...]
Website: https://uniteom.org/ Media Contact A Cure In Sight Founding Member, UNITE OM Email: melody@acureinsight.org Website: https://uniteom.org/ FOR IMMEDIATE RELEASE UNITE OM Launches Global Coalition to Bring the Ocular Melanoma Community Together International coalition brings nonprofit organizations and patient advocates [...]
Read full article: The study: Moffitt researchers analyzed 60 advanced melanoma patients from four clinical trials to understand why TIL immunotherapy helps some patients but not others. Cell quality matters: Infusions with more CD8+ T cells and "stem-like memory" T cells were linked [...]
Read full article: Multidisciplinary care is improving the patient experience and treatment planning. Liquid biopsies may help detect and monitor uveal melanoma with a simple blood test. New vision-preserving approaches are improving quality of life after treatment. Artificial intelligence may help identify suspicious [...]
Read full article: DYP688 is a new targeted therapy developed specifically for GNAQ- and GNA11-mutated melanomas. The treatment delivers medicine directly to PMEL-positive melanoma cells. Researchers observed tumor shrinkage or disease control in many participants. Most treatment-related side effects were manageable and did [...]
Read full article: Researchers completed a successful Phase I safety trial of the investigational oral drug 7HP349. The study found the medication was well tolerated, with no treatment-related serious adverse events reported. The therapy is designed to strengthen the body's immune response rather [...]
Read full article: Researchers identified BAP1 gene abnormalities as a strong predictor of metastatic uveal melanoma. Combining BAP1 changes with chromosome 1 alterations improved the accuracy of metastasis risk prediction. The new classification system successfully separated patients into four distinct metastatic risk groups. [...]
